Samet Oncel

Dr. Samet Oncel

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
MSMeral Seferoğlu
Meral Seferoğlu
ATAbdulkadir Tunç
Abdulkadir Tunç
ASAli Özhan Sıvacı
Ali Özhan Sıvacı
SOSamet Oncel
Samet Oncel
TDTuğba Düztaban
Tuğba Düztaban
MÖMuhammed Furkan Öztürkci
Muhammed Furkan Öztürkci
Background: Mobility impairments in multiple sclerosis (MS) significantly affect quality of life. This study evaluated the clinical utility and sensitivity of the Backward Timed 25-Foot Walk Test (B-T25FW) and its associations with key clinical measures in MS. Methods: A cross-sectional study was conducted with 129 ambulatory patients with MS from two centers. Disability (Expanded Disability Status Scale, EDSS), cognition (Symbol Digit Modalities Test, SDMT), manual dexterity (Nine-Hole Peg Test, 9HPT), fatigue, and forward and backward walking were assessed. Correlation and receiver operating characteristic (ROC) analyses were performed. Results: The participants included in the study were 76% female, with a mean age of 38 years, and the majority were diagnosed with relapsing–remitting MS (86.8%). Backward and forward walking times significantly correlated with key clinical measures, including the EDSS, SDMT, and 9HPT. Backward walking times showed moderate correlations with EDSS (r = 0.469) and weaker but significant correlations with 9HPT (r = 0.452) and disease duration (r = 0.245). Both walking tests were negatively correlated with SDMT scores. For prognostic purposes, forward walking exhibited slightly higher predictive power compared to backward walking. Conclusions: The B-T25FW is a clinically relevant, practical, and sensitive tool for assessing mobility impairments in individuals with MS. Its integration into clinical practice could complement forward walking assessments, enhancing disease monitoring and guiding interventions. Future research should validate its longitudinal utility.

13 August 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
ATAbdulkadir Tunç
Abdulkadir Tunç
GDGurkan Danisan
Gurkan Danisan
OTOnur Taydas
Onur Taydas
AKAhmet burak Kara
Ahmet burak Kara
SOSamet Oncel
Samet Oncel
MÖMustafa Özdemir
Mustafa Özdemir
Background: Alterations in the cerebral venous system have been increasingly recognized as a significant component of the pathophysiology of multiple sclerosis (MS). This study aimed to explore the relationship between venous sinus diameter and MS to understand potential vascular alterations in MS patients compared with controls. We sought to determine whether these alterations were correlated with disease characteristics such as duration, lesion type, and disability score. Methods: This study included 79 MS patients diagnosed according to the 2017 McDonald criteria and 67 healthy individuals. Magnetic resonance imaging (MRI) scans via a 1.5 Tesla system provided measurements of the superior sagittal sinus, right and left transverse sinus, sinus rectus, and venous structures. Statistical analysis was conducted via SPSS, employing independent sample t tests, ANOVA, chi-square tests, and Pearson correlation analysis, with the significance level set at p < 0.05. Results: This study revealed significant differences in venous sinus diameter between MS patients and controls, with MS patients exhibiting larger diameters. Specifically, patients with brainstem and spinal lesions had larger diameters in certain sinus regions. No significant correlations were found between venous sinus diameter and demographic factors, expanded disability status scale scores, or lesion counts. However, a significant increase in perivenular lesions was noted in patients with longer disease durations. Conclusions: The findings indicate notable vascular alterations in MS patients, particularly in venous sinus diameters, suggesting a potential vascular component in MS pathology. The lack of correlation with conventional clinical and MRI metrics highlights the complexity of MS pathology. These insights underscore the need for further research, particularly longitudinal studies, to elucidate the role of venous changes in MS progression and their potential as therapeutic targets.

30 September 2026 in Sakarya Medical Journal
Verified
Journal Article
Open access
SOSamet Oncel
Samet Oncel
ATAbdulkadir Tunç
Abdulkadir Tunç
DGDerya Kara Genç
Derya Kara Genç
GKGülümser Büşranur Yurtsev Kaplan
Gülümser Büşranur Yurtsev Kaplan
BÖBüşra Bozdoğan Özyavuz
Büşra Bozdoğan Özyavuz
TATürkan Acar
Türkan Acar
Objective: Subarachnoid hemorrhage (SAH) remains a substantial neurological emergency. Data on diagnostic timing, etiologic distribution, and prognostic factors across SAH subtypes are limited in emergency department (ED)-based cohorts.Methods: We retrospectively reviewed 110 patients presenting with suspected SAH between 2018-2024. Demographic and clinical features, imaging patterns, etiology, comorbidities, complications, and treatments were extracted. Outcomes were assessed at one month using Glasgow Coma Scale (GCS), modified Rankin Scale (mRS), and Hunt & Hess (H&H) grades.Results: The cohort (mean age 53.2 ± 16.8 years; 60.9% male) frequently exhibited hypertension (24.5%). Leading presentations were trauma (32.7%) and headache (33.6%); sentinel headache occurred in 12.7%. Nearly all patients (89.1%) underwent non-contrast CT within 6 hours. SAH etiology was traumatic (53.6%), aneurysmal (24.5%), and spontaneous (21.8%). Mean admission GCS was 12.6 ± 3.6. Complication rates were low (rebleeding 4.5%, delayed cerebral ischemia 2.7%, vasospasm 0.9%). Traumatic SAH, despite lower admission GCS, was associated with higher rates of functional improvement (GCS 61.0%, mRS 74.6%) and fewer comorbidities compared to spontaneous/aneurysmal subtypes. Younger age (mRS and H&H analyses) and absence of comorbidities (GCS analysis) were associated with improvement, whereas patients who were fully alert at admission were less likely to meet the improvement criterion. Sentinel headache and nimodipine use clustered among non-improvers, likely reflecting disease severity. CT bleed pattern and H&H grade were not significantly associated with outcome.Conclusions: Traumatic SAH predominated in this ED-based cohort and showed more favourable one-month recovery than spontaneous subtypes. Admission clinical severity was the factor most consistently associated with functional change, although this association is constrained by the ceiling inherent to a change-based outcome definition. Early imaging and rigorous vascular evaluation remain essential, and larger etiology-stratified studies using absolute outcome measures are warranted.

11 September 2026 in Medicina
Verified
Journal Article
Open access
PDF file
SOSamet Oncel
Samet Oncel
MSMeral Seferoğlu
Meral Seferoğlu
SÖSami Ömerhoca
Sami Ömerhoca
SAsemanur aksu aksu
semanur aksu aksu
EÇErtuğrul Çınar
Ertuğrul Çınar
NINilüfer Kale İçen
Nilüfer Kale İçen
Background and Objectives: Visual evoked potentials (VEPs) are established tools for detecting optic pathway involvement in multiple sclerosis (MS); however, the distinct clinical significance of longitudinal changes in latency and amplitude remains unclear. This exploratory study aimed to evaluate the clinical utility of serial VEP assessments in patients with relapsing–remitting MS (RRMS) by examining the associations between temporal changes in latency and amplitude and concurrent markers of disease activity and disability. Materials and Methods: We retrospectively analyzed 83 patients with RRMS from three centers who underwent at least two pattern-reversal VEP assessments ≥ 1 year apart. Patients with recent optic neuritis were excluded. Longitudinal changes in VEP latency and amplitude were evaluated in relation to relapse activity during the same inter-assessment interval, baseline MRI and CSF findings, and disability assessed by the Expanded Disability Status Scale (EDSS). Sensitivity analyses were stratified and adjusted for disease-modifying therapy (DMT) efficacy tier, and progression independent of relapse activity (PIRA) was examined using a formal definition. Results: Over a median follow-up of 2 years, 43.4% of patients developed P100 latency prolongation, which was independently associated with a higher annualized relapse rate during the same interval (odds ratio [OR] 2.91, p = 0.005; area under the curve (AUC) 0.72 for concurrent on-study relapse activity), an association that persisted after adjustment for DMT efficacy tier, but not with disability worsening. In contrast, 56.6% of patients exhibited amplitude reduction, which was associated with greater disability accumulation at the group level, with higher EDSS scores at follow-up despite similar baseline values (p < 0.05); the corresponding inverse correlation between amplitude decline and EDSS change was only nominally significant (ρ = −0.231, p = 0.036), did not survive correction for multiple comparisons, and was attenuated after adjustment for baseline EDSS. Formally defined PIRA events were rare (n = 3), precluding inference. Baseline magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) findings differed in the latency group, with fewer MRI lesions and a lower immunoglobulin G (IgG) index, whereas no corresponding differences were observed in the amplitude group. Conclusions: In this exploratory cohort, longitudinal prolongation of VEP latency was associated with concurrent relapse activity, whereas amplitude decline showed a weaker, group-level association with disability. These findings are consistent with, but do not demonstrate, distinct inflammatory and neurodegenerative substrates, and warrant prospective validation before serial VEP monitoring can inform individualized management in MS.